title: Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
abstract: OBJECTIVE
  To determine the impact of biological subtypes defined by hormonal receptors and human epidermal growth factor receptor-2 status on risk of recurrence in women with invasive breast cancer treated with breast-conserving therapy.
  
  
  METHODS
  Between 2001-2005, we observed 590 women with invasive breast cancer. They underwent conservative surgery, adjuvant radiotherapy and hormonotherapy or chemotherapy. None received adjuvant trastuzumab. The Kaplan-Meier method was applied to calculate for the 36-month and 60-month rates of locoregional recurrence-free survival and overall survival.
  
  
  RESULTS
  The overall 36- and 60-month actuarial Kaplan-Meier survival rates were 98.5% and 97.7%, respectively; the locoregional recurrence-free survival rates were 95.2% and 91.2%, respectively. Locoregional recurrence rate was significantly greater in patients with human epidermal growth factor receptor-2 (15.2% vs. 5.3%, p<0.001).
  
  
  CONCLUSIONS
  Patients with hormone receptor-negative or human epidermal growth factor receptor-2-positive T1-T2 breast cancer seem to have a greater risk of disease recurrence.
authors.affiliation: Department of Radiation Oncology, G. d'Annunzio University, SS. Annunziata Hospital, via dei Vestini, 66100, Chieti, Italy. marianna.trignani@unich.it.
authors.forename: Giampiero Ausili
authors.initials: GA
authors.lastname: Cefaro
authors.forename: Domenico
authors.initials: D
authors.lastname: Genovesi
authors.forename: Marianna
authors.initials: M
authors.lastname: Trignani
authors.forename: Marta
authors.initials: M
authors.lastname: DI Nicola
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D018275:Carcinoma, Lobular / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
keywords: HER2; breast cancer; locoregional recurrence; radiotherapy